Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $12 from $15 and keeps an Outperform rating on the shares following quarterly results. The firm says key milestones remain on track; most immediately dose-escalation results from the combination of ORIC-944 with apa/darolutamide.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC: